What this guide adds
The short guide on this site to what personalized compounded semaglutide is covers the molecule, the regulation and the trials. This one is the longer, practical companion: the parts of the process that people ask about once they are seriously considering treatment. Who prepares the medication and under what rules, how the prescription reaches a pharmacy, what arrives and how it is measured, how it is stored, what the FDA specifically warns about, and how Bodi Envi’s program handles each step.
This is general information and not medical advice. Personalized Compounded semaglutide is not FDA-approved and is not equivalent to Wegovy® or Ozempic®. The clinical trials described on this site studied the branded products and not compounded versions. Your licensed provider is the person to ask about your own treatment.
What personalized compounded semaglutide is
Semaglutide is the active ingredient in two FDA-approved products from one manufacturer. Wegovy® is approved, per its prescribing information, to reduce excess body weight and maintain weight reduction long term in adults with obesity or with overweight and a weight-related condition, among other indications. Ozempic® is approved, per its own label, to improve blood sugar control in adults with type 2 diabetes and to reduce certain cardiovascular and kidney risks in that population. Brand names are trademarks of their respective owners, and Bodi Envi is not affiliated with them.
Personalized Compounded semaglutide is that same molecule prepared by a compounding pharmacy for one patient. The FDA’s human drug compounding page defines compounding as a practice in which a licensed pharmacist, a licensed physician, or in an outsourcing facility a person under a pharmacist’s supervision, combines, mixes or alters ingredients of a drug to create a medication tailored to the needs of an individual patient. What you receive is a product the pharmacy made for your prescription, not a finished product from the manufacturer’s line.
The single most important fact about it is what the FDA states on that same page: compounded drugs are not FDA approved, which means the agency does not review their safety, effectiveness or quality before they are marketed. A compounded drug is not a generic either, as the FDA’s questions and answers page explains. Bodi Envi puts the consequence plainly: personalized compounded semaglutide is not FDA-approved and is not equivalent to FDA-approved products.
Who may prepare it and under what rules
Federal law describes two kinds of compounder, and they are regulated differently. The FDA’s page on compounding laws and policies explains that section 503A of the Federal Food, Drug and Cosmetic Act sets the conditions under which drugs compounded by a licensed pharmacist in a state-licensed pharmacy, or by a physician, are exempt from the requirements for FDA approval, current good manufacturing practice and full labelling. One of those conditions is that the drug must be compounded on the basis of a valid patient-specific prescription. Section 503B, added in 2013, created outsourcing facilities, which are subject to current good manufacturing practice, are inspected by the FDA on a risk-based schedule, and may compound without a patient-specific prescription for a provider’s office stock.
Day to day oversight differs too. According to the FDA’s questions and answers page, state boards of pharmacy generally have primary responsibility for overseeing state-licensed pharmacies that are not registered as outsourcing facilities, while the FDA conducts surveillance and for-cause inspections of them and primarily oversees the 503B facilities. Drugs compounded under 503A are not subject to current good manufacturing practice requirements, though the FDA notes that other federal law, including provisions on insanitary conditions, applies wherever compounding happens.
Bodi Envi’s prescriptions go to third party U.S. 503A licensed compounding pharmacies. Bodi Envi publishes that applicable state boards of pharmacy regulate and inspect those pharmacies, and that pharmacy operations and sterile compounding practices are subject to applicable U.S. Pharmacopeia standards. VialsRx is the current pharmacy partner for applicable GLP-1 prescriptions, and pharmacy availability may vary by program and patient location. The guide on this site to whether personalized compounded semaglutide is legal in 2026 goes further into the shortage rules and what the FDA has said about them.
How the prescription works
Because a 503A pharmacy compounds only on a patient-specific prescription, the prescription is the foundation of the whole arrangement, and it is why personalized compounded semaglutide cannot legitimately be bought without a licensed prescriber having evaluated you. The FDA’s statement on unapproved GLP-1 drugs lists, among the warning signs of an unsafe seller, one that does not require a screening and prescription by a licensed doctor before providing medicine, and one that does not have a licensed doctor available to answer questions afterwards.
Through Bodi Envi the sequence is the one it publishes. You complete an online health assessment. A licensed provider, through Wasef Health, PC for applicable programs, reviews it and may ask for clarifying information. If the provider determines that treatment is appropriate, a prescription is issued and sent to a pharmacy partner for dispensing and fulfilment. Not every patient is approved; prescriptions are issued only when a licensed provider deems them appropriate for your health profile, and completing the assessment or paying for a program does not guarantee one.
The assessment asks about your health history in detail because the Wegovy® label sets out who the approved product is not for, and a provider applies the same knowledge to a compounded prescription. The label’s contraindications are a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and a known serious hypersensitivity to semaglutide. Its warnings cover pancreatitis, gallbladder disease, low blood sugar when combined with insulin or a sulfonylurea, kidney injury from dehydration, severe gastrointestinal reactions, diabetic retinopathy complications and several others. The safety guide on this site goes through them one by one. Answer the assessment completely; a provider who does not know about a condition or a medication cannot decide safely.
What arrives and how it is measured
The manufacturer’s product comes as a pen that delivers a fixed dose. Personalized Compounded semaglutide typically comes as a vial of solution that you draw up with a syringe, though the exact presentation depends on the pharmacy. That difference is the origin of the FDA’s most specific concern. Its statement on unapproved GLP-1 drugs reports multiple adverse events, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide, resulting from patients measuring and self-administering incorrect doses and in some cases from providers miscalculating doses. The agency encourages patients to talk with their provider or the compounder about how to measure and administer the intended dose.
The practical rules follow from that. Use the measuring instructions on the pharmacy label and any instructions your care team gives you, and ask through the patient portal if anything is unclear before you inject. Use a new sterile needle and syringe for every dose; the FDA says reusing them can contaminate the medication. Never change your own dose. And know what a dose looks like in the units on your syringe, because a vial’s concentration can differ from one pharmacy to another and from the branded pen.
The FDA also notes that compounded GLP-1 medications may be dispensed in vials containing multiple doses, and recommends that a multi-dose vial of a sterile medication be discarded 28 days after first use, even if medication remains and even if the compounder’s instructions say it can be used longer, because of the increased risk of contamination after that point.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
What the label says about the schedule
The Wegovy® label describes a dose that starts low and rises in steps, and it explains why: the escalation exists to reduce the risk of gastrointestinal adverse reactions. The label’s schedule starts at 0.25 mg once weekly for four weeks, then 0.5 mg, 1 mg and 1.7 mg for four weeks each, then a maintenance dose from week seventeen, with 1.7 mg and 2.4 mg listed as maintenance doses for weight reduction in adults and a further increase to 7.2 mg described for adults who tolerate 2.4 mg and for whom more weight reduction is clinically indicated. The label allows a provider to delay a step by four weeks if a dose is not tolerated, and says that if two or more consecutive doses are missed, escalation should be restarted at a lower dose.
That schedule describes the branded product. With a compounded prescription, your provider sets your starting dose, decides when and whether to increase it, and can hold or lower it. The FDA’s statement specifically reports adverse events in patients prescribed personalized compounded semaglutide in doses beyond what the approved label describes, whether by a larger single dose, more frequent dosing or faster escalation, and asks providers to be vigilant about dosing and titration. Bodi Envi’s pricing does not increase based solely on dosage strength, so a dose decision on its programs is clinical rather than financial. The guide on this site to what the semaglutide label schedule looks like has the full table.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
Storage and handling
The storage instructions for your compounded medication come from the pharmacy that prepared it, on the label attached to your vial, and they are the ones to follow. The branded label is a useful reference for what the molecule needs. The Wegovy® label says to store the single-dose pen in the refrigerator between 36°F and 46°F, that before its cap is removed it may be kept between 46°F and 86°F for up to 28 days, that it must be protected from light and kept in its carton, and that it must not be frozen or used if it has been frozen. The FDA adds that injectable GLP-1 drugs require refrigeration and that it has received complaints of compounded products arriving warm or with inadequate ice packs; it recommends not using any injectable GLP-1 drug that arrives warm or with insufficient refrigeration.
If your medication arrives warm, or you are unsure whether it has been stored correctly, contact the pharmacy before using it. Bodi Envi’s refund policy asks patients with a dispensing concern to contact the dispensing pharmacy promptly after delivery, inside the window the policy states, using the details on the prescription label. The storage guide on this site covers refrigeration and handling in more depth.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
What the research shows, and what it does not
The reference trial for semaglutide in weight management is STEP 1, published by Wilding and colleagues in the New England Journal of Medicine in 2021. According to the abstract on PubMed, 1,961 adults with obesity or overweight and no diabetes were randomized to 68 weeks of once weekly semaglutide 2.4 mg or placebo alongside a lifestyle intervention. The mean change in body weight was 14.9 percent with semaglutide and 2.4 percent with placebo; 86.4 percent of the semaglutide group lost at least 5 percent of their body weight. Nausea and diarrhea were the most common adverse events and were typically transient and mild to moderate.
STEP 1 studied Wegovy®, the branded product, at its approved dose. It did not study personalized compounded semaglutide, and no trial of that scale has. A compounded product’s formulation, concentration, container and quality controls all differ from the branded product’s, and nothing has been published that shows the two behave the same way. The FDA’s concerns statement also notes that many of the adverse events it has received for compounded products appear consistent with those of the approved versions, but that pharmacies operating under 503A are not required by federal law to report adverse events to the FDA, so reports are likely to be underrepresented. A trial result, in other words, is evidence about the molecule in the approved product; it is not evidence about the vial in your refrigerator. Individual experiences and outcomes vary.
Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.
At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.
The FDA’s specific warnings
The FDA’s statement on unapproved GLP-1 drugs, dated September 1, 2026, is the single document most worth reading before starting compounded treatment, and its warnings are summarized here as it states them. Compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug. Patients should obtain a prescription from their doctor and fill it at a state-licensed pharmacy. Some personalized compounded semaglutide products have used salt forms, semaglutide sodium and semaglutide acetate, which are different active ingredients from the one in the approved drugs, for which the agency has no information on chemical and pharmacological equivalence and no lawful basis for use in compounding. Fraudulent products have been marketed with labels naming pharmacies that do not exist or that did not make the product. Products falsely labelled for research purposes or not for human consumption have been sold to consumers with dosing instructions. And the agency lists warning signs of an unsafe seller, including claims that a compounded drug is the same as an approved one, prices that seem too good to be true, medicine that looks different from before or arrives damaged or without instructions, and no licensed doctor available afterwards.
The FDA asks patients and providers to report adverse events or quality problems with any medication, including compounded ones, to its MedWatch program.
How Bodi Envi’s program handles each step
Bodi Envi is a LegitScript-certified U.S. telehealth platform that connects eligible adults with licensed healthcare providers for personalized medical weight-management care. It is not a medical practice, pharmacy or medication manufacturer, and it does not compound anything. Clinical services for applicable programs are provided by Wasef Health, PC. Prescriptions are dispensed by third party U.S. 503A licensed compounding pharmacies, with VialsRx the current partner for applicable GLP-1 prescriptions.
The published price for the personalized compounded semaglutide program is $155 per month billed monthly, $145 per month on a three month plan paid as $435, $135 per month on a six month plan paid as $810, and $125 per month on a twelve month plan paid as $1,500. The price includes the assessment, provider review, messaging with your care team through the patient portal, a GLP-1 ebook and diet plan, and the medication when a provider prescribes it. Pricing does not increase based solely on dosage strength. Cancellation and refunds are governed by the published cancellation policy: Bodi Envi accepts cancellation through the patient portal or by email to info@bodienvi.com, but once a provider review is complete and a prescription is sent to the pharmacy, that order cannot be cancelled, and dispensed medications are non-refundable once an order has been processed or shipped.
Everything here is general information and not medical advice. Personalized Compounded semaglutide is not FDA-approved, the trials cited did not study it, and a licensed healthcare provider determines whether treatment is appropriate for each individual patient. Your provider is the person to ask.